8-KEarnings & ResultsRegulation FDExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Apr 29, 2022)

Filed April 29, 2022For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb (BMY) has filed an 8-K report on April 29, 2022, detailing their financial results for the first quarter of 2022. The report primarily serves to furnish the company's earnings press release and supplemental financial information, which were made public on the same date. Investors should note that this filing is informational, providing access to the detailed Q1 2022 financial performance and operational updates presented by the company. The filing incorporates by reference the Earnings Press Release (Exhibit 99.1) and Supplemental Information (Exhibit 99.2) which contain the core financial data. Additionally, a presentation (Exhibit 99.3) shared during the Q1 2022 earnings call is included, offering insights into financial and operating initiatives. While the presentation includes non-GAAP financial measures, reconciliations to GAAP are available in the supplemental information.

Key Highlights

  • 1BMY announced its first quarter 2022 financial results on April 29, 2022.
  • 2The 8-K filing furnishes the company's Q1 2022 Earnings Press Release (Exhibit 99.1).
  • 3Supplemental financial information (Exhibit 99.2) is also provided for investors.
  • 4A presentation on financial and operating initiatives (Exhibit 99.3) from the Q1 2022 earnings call is available.
  • 5The filing includes references to non-GAAP financial information, with reconciliations provided in the supplemental materials.
  • 6Information furnished under Item 7.01 is not considered 'filed' for certain regulatory purposes.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially provide investors with access to Bristol Myers Squibb's financial results for the first quarter of 2022, including their earnings press release and supplemental financial information.

The detailed Q1 2022 financial results can be found in the Earnings Press Release (Exhibit 99.1) and the Supplemental Information (Exhibit 99.2) furnished with this 8-K filing. These documents are also available on the company's website.

This 8-K filing primarily reports on past financial results and related materials. Specific forward-looking guidance or outlook would typically be detailed within the Earnings Press Release (Exhibit 99.1) and potentially the Bristol Myers Presentation (Exhibit 99.3), which should be reviewed for such information.

The filing notes that the accompanying presentation includes non-GAAP financial measures. Reconciliations between non-GAAP and comparable GAAP financial measures are available in the Supplemental Information (Exhibit 99.2) and explained in the Earnings Press Release (Exhibit 99.1).